Skip to main content

Table 5 Baseline clinical and biological characteristics of coagulopathic patients who died early (within 48 hours)

From: Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials

  Placebo group rFVIIa group
  (n = 10) (n = 11)
Age (years) 39 ± 12 30 ± 9
Gender   
   Men 7 (70%) 11 (100%)
   Women 3 (30%) 0 (0%)
Type of trauma   
   Penetrating 4 (40%) 8 (73%)
   Blunt 6 (60%) 3 (27%)
Injury severity score 34 ± 13 37 ± 8
Number of body regions injured   
   1 1 (10%) 2 (18%)
   2–3 6 (60%) 7 (64%)
   >3 3 (30%) 2 (18%)
   Unknown 0 (0%) 0 (0%)
Systolic blood pressure (mm Hg) 87 ± 22 103 ± 34
Mean arterial pressure (mm Hg) 63 ± 17 68 ± 32
Body temperature (°C) 34.1 ± 2.5 35.2 ± 1.2
pH 7.28 ± 0.10 7.23 ± 0.09
Hematocrit (percentage) 26 ± 14 19 ± 4
aPTT (seconds) 93 ± 44 78 ± 32
PT (seconds) 25 ± 6 25 ± 7
Fibrinogen (g/l) 0.8 ± 0.3 0.7 ± 0.3
Platelets (× 109) 42 ± 51 61 ± 35
Causes of death   
   Exsanguination 7 (70%) 9 (82%)
   Organ failure 3 (30%) 1(9%)
   Cardiac injury 0 (0%) 1 (9%)
  1. aPTT, activated partial thromboplastin time; PT, prothrombin time; rFVIIa, recombinant activated factor VII.